Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Jureidini, Jon N.; | McHenry, Leemon B. | Mansfield, Peter R.
Affiliations: Discipline of Psychiatry, University of Adelaide, Adelaide, South Australia | Department of Philosophy, California State University, Northridge, CA, USA | Discipline of General Practice, University of Adelaide, Adelaide, South Australia
Note: [] Address for correspondence: Jon N. Jureidini, Department of Psychological Medicine, Women's and Children's Hospital, North Adelaide, 5006 Australia. Tel.: +61881617226; E-mail: [email protected].
Abstract: Selective reporting is prevalent in the medical literature, particularly in industry-sponsored research. In this paper, we expose selective reporting that is not evident without access to internal company documents. The published report of study 329 of paroxetine in adolescents sponsored by GlaxoSmithKline claims that “paroxetine is generally well tolerated and effective for major depression in adolescents”. By contrast, documents obtained during litigation reveal that study 329 was negative for efficacy on all 8 protocol specified outcomes and positive for harm.
Keywords: Selective reporting, SSRI, litigation, industry sponsorship
DOI: 10.3233/JRS-2008-0426
Journal: International Journal of Risk and Safety in Medicine, vol. 20, no. 1-2, pp. 73-81, 2008
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]